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Abstract 
Apoptosis is an essential process in development and tissue maintenance. The tumor 
suppressor protein p53 initiates apoptosis through transactivation of pro-apoptotic genes 
when cellular stress is detected. This study identifies a regulatory role for the lysine 
demethylase, PHF8, in the p53-mediated apoptosis pathway. We initially suspected PHF8 of 
demethylating the adaptor protein Numb, however found this to be untrue. PHF8 has been 
found to have oncogenic properties including an anti-apoptotic effect, however how PHF8 
negatively affects apoptosis has not been previously investigated. We found PHF8 inhibits 
translation of the pro-apoptotic genes TP53, BAX and CASP3. Chromatin 
immunoprecipitation revealed PHF8 binding to the TP53 and CASP3 gene promoters. 
H3K27 methylation at these promoters was significantly decreased with doxorubicin 
treatment in the presence of PHF8, and significantly increased when PHF8 was knocked 
down. Since methylated H3K27 is a repressive mark, we suspect other transcription factors 
or histone modifying proteins to be involved.  
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Chapter 1  
1 Introduction 
Post-translational modifications (PTM) play an important role in protein regulation. 
There are many different types of PTMs including phosphorylation, acetylation, 
glycosylation, as well as methylation an area of PMT research that is under rapid growth. 
The first histone methyltransferase, Su(var)3-9 human 1 (SUV39H1) was discovered in 
2000 (Rea et al., 2000). Methylation of histone tail residues has become well 
characterized and is known to affect the regulation of gene expression by recruiting or 
inhibiting other regulatory proteins (Zhang and Reinberg, 2001). Methyltransferases have 
since been found to target either lysine or arginine histone tail residues (Zhang and 
Reinberg, 2001). Interestingly, until the discovery of the first demethylase, lysine specific 
demethylase 1 (LSD1), which removes methyl groups from histone H3 lysine 4, 
methylation was thought to be a static modification (Shi et al., 2004). Another relatively 
recent discovery was the methylation of non-histone proteins. The p53 protein was the 
first non-histone protein discovered to undergo post-translational methylation (Chuikov 
et al., 2004) and since this discovery, many non-histone methylation targets have been 
identified (Huang and Berger, 2008). Lysine methylation can act as either a positive or 
negative regulatory signal, existing in three states, mono-, di- and tri-methylation 
(Margueron et al., 2005). Each different methylation state on the same amino acid can 
elicit a different regulatory effect on the protein. Methylation has been found to play a 
role in regulating nearly all cellular processes, including cell proliferation, differentiation 
and apoptosis to name a few (Shi and Whetstine, 2006; Meek and Anderson, 2009). This 
study will focus on the role of methylation in regulating apoptosis. 
1.1 Apoptosis 
Cells death is an important process for the development and survival of multicellular 
organisms. During development, cells are required to undergo apoptosis in order for 
organ development and appendages to form (Horvitz, 1999; Renehan et al., 2001). By 
having a controlled manner of disposing of unwanted cells, an immune response is 
2 
 
avoided (Renehan et al., 2001). Apoptosis is also critical to the general maintenance and 
protection of tissues. Controlled cell death is the organism’s way of disposing cells that 
are no longer necessary or could become harmful and cause damage to the tissue 
(Renehan et al., 2001). For example when a cell acquires DNA damage that cannot be 
repaired, it is in the body’s best interest to prevent this cell from replicating and remove 
it, avoiding daughter cells which may have harmful mutations. Improper repair of DNA 
damage by avoiding cell cycle arrest and failure of cells to undergo apoptosis are 
hallmarks of cancer (Hanahan and Weinberg, 2000).  
Apoptosis signalling occurs in response to a variety of different pathological and 
physiological stimuli. Depending on which stimuli the cell is responding to, different 
pathways and proteins will become active. The two main types of apoptotic pathways are 
the extrinsic pathway and the intrinsic pathway (Elmore, 2007). The extrinsic pathway 
involves an external ligand binding to a trans-membrane death receptor [i.e. Tumor 
necrosis factor receptor (TNFR), first apoptosis signal (FAS) receptor, etc.] (Locksley et 
al., 2001), whereas the intrinsic pathway results from an internal signal such as oncogene 
expression, excess DNA damage, hypoxia, toxins, or radiation (Elmore, 2007).  
1.2 Tumor suppressor protein p53 
1.2.1 Discovery of p53 
The p53 protein was originally identified in 1979 as a protein found to bind the large ‘T’ 
antigen in simian virus 40 (SV40) transformed cells (Kress et al., 1979; Lane and 
Crawford, 1979; Linzer and Levine, 1979). It was identified as a 53kDa protein and 
therefore was named p53, representing a protein with a molecular weight of 53 kDa 
(Crawford, 1983). Since its discovery, p53 has been identified as a tumour suppressor 
protein in response to its cellular protective functions. In this regard, the p53 protein  
protects the cell in a number of ways such as regulating cell cycle check points (Kuerbitz 
et al., 1992), DNA damage response and repair, cell stress response and apoptosis 
induction (Meek, 2009), as well as regulating the inhibition of angiogenesis (Tokino and 
Nakamura, 2000). These functions are regulated by p53 through its role as a transcription 
factor. Therefore, p53 exerts its protective effects on cells by up-regulating the 
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transcription of genes required for these processes (Riley et al., 2008). The p53-induced 
gene expression includes the genes of proteins required for apoptosis such as pro-
apoptotic proteins B-cell lymphoma (Bcl)-2-associated x protein (BAX) (Miyashita et al., 
1994), Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) (Oda et al., 2000) and 
p53 up-regulated modulator of apoptosis (PUMA) (Nakano and Vousden, 2001), as well 
as genes required for the cell cycle arrest and DNA damage response (Levine, 1997) such 
as the cell cycle cyclin dependent kinase (cdk) inhibitor p21 (El-Deiry, 1993). Although 
p53 functions largely as a transcription factor, there is also evidence that p53 directly 
regulates proteins during apoptosis such as BAX (Chipuk et al., 2004).  
Critically, the p53 protein has been reported to be deregulated in at least 50% of cancers 
(Soussi and Berude, 2001). In these cases, the p53 gene itself is either mutated or there 
are mutations in one of the many proteins that regulate p53 function or stability. For this 
reason, p53 has been studied intensely over the years in hopes to treat these cancers by 
reversing the negative effect on p53 function. However, our understanding of p53 
function and its regulation remains incomplete and should remain an important focus of 
study for the development of new therapies for personalized cancer treatment.  
1.2.2 p53 mediated apoptosis 
The p53 mediated apoptosis pathway is induced by a number of signals (Elmore, 2007). 
These include aberrant oncogene expression, excessive DNA damage and hypoxia 
(Elmore, 2007; Gotz and Montenarh, 1995). In this manner, p53 is able to activate both 
the intrinsic and extrinsic apoptosis pathways. The extrinsic apoptosis pathway can be 
activated by p53 transactivation of the FAS receptor. Whereas, the p53 mediated intrinsic 
apoptosis pathway signalling (Figure 1.1) involves activation of pro-apoptotic Bcl-2 
family proteins such as BAX, facilitating the release of cytochrome C from the 
mitochondria. Since p53 plays such an important protective role, it is constantly being 
synthesized in cells, but is also being constantly degraded, stabilized only when required 
by the cell. This constant synthesis of p53 allows for a quick response to cellular stress. 
Ataxia-telangiectasia, mutated (ATM) and ATM and Rad3-related (ATR) are two kinases 
which sense genotoxic stress (Yang et al., 2004). When DNA damage is present, these 
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two kinases become activated. They can either directly activate p53 by phosphorylating 
p53 themselves or indirectly by activating other proteins which can then act on p53 
(Yang et al., 2004). Both ATM and ATR have been found to phosphorylate a number of 
residues on p53 including serine 15 (Ser15) which leads to p53 activation (Canman et al., 
1998; Tibbetts et al., 1999). ATM has been found to phosphorylate Ser46 of p53 which 
has been suggested to lead to p53’s transactivation of proapoptotic genes (Saito et al., 
2002).  
Activation of p53 allows it to activate the expression of proapoptotic genes PUMA, BAX 
and Phorbol-12-myristate-13-acetate-induced protein 1 (NOXA) (Nakano and Vousden, 
2001; Miyashita et al., 1994; Oda et al., 2000). These proteins inhibit Bcl-2, an anti-
apoptotic protein, while stimulating the release of cytochrome C from the mitochondria. 
BAX binds to anti-apoptotic Bcl-2 family members when the cell is not undergoing 
apoptosis, which inhibits its apoptotic function (Oltvai et al., 1993). PUMA is able to 
inhibit the anti-apoptotic Bcl-2 proteins, releasing BAX and allowing it to form dimers 
with other pro-apoptotic Bcl-2 family members (Kuwana et al., 2005; Follis et al., 2013). 
These BAX dimers can them permeabilize the outer mitochondrial membrane causing the 
release of cytochrome C (Gross et al., 1999). Cytochrome C is then able to bind to and 
activate apoptosis-protease activating factor 1 (Apaf-1) hepta-oligomer along with 
adenosine tri-phosphate (ATP), forming the apoptosome (Garrido et al., 2006). The 
apoptosome is a complex which cleaves pro- cysteine-dependent aspartate-directed 
protease-9 (pro-Caspase9) to activate it and causes subsequent cleavage and activation of 
downstream caspases (Acehan et al., 2002). This leads to fragmentation of the nuclear 
envelope, degradation of nuclear and cytoskeletal proteins, as well as the degradation of 
chromosomal DNA (Elmore, 2007). The apoptotic cells and fragments are engulfed by 
phagocytes through the recognition of a phosphatidylserine on the cell surface (Wu et al., 
2006). This phosphatidylserine is normally found within the membrane bi-layer, however 
when cells undergo apoptosis it is flipped out to be recognized on the surface of the cell 
(Fadok et al., 1998).  
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Figure 1.1: p53 mediated apoptosis signaling pathway. DNA damage, aberrant 
oncogene expression and other stresses signal the activation of kinases (ATM, ATR) 
which activate p53 through phosphorylation as well as other proteins which inhibit mouse 
double minute 2 homologue (MDM2) polyubiquitination of p53. The activation and 
stabilization of p53 leads to transactivation of genes encoding proteins required for 
apoptosis such as BAX, PUMA and Noxa. P53 is also believed to directly activate BAX. 
Activation of PUMA, NOXA and BAX lead to the release of cytochrome C from the 
mitochondria. Cytochrome C then binds to Apaf-1 along with ATP activating Apaf-1 and 
forming the apoptosome. This complex is then able to cleave pro-caspase9 into its active 
form Caspase9. This is the initiation step of the Caspase signaling cascade which 
commits the cell to apoptosis. (Węsierska-Gądek and Schmidt V, 2007; 
http://www.cancer-therapy.org/CT/v5/B/HTML/25._We%3Fsierska-
Ga%3Fdek_and_Schmid,_203-212.html) 
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1.2.3 Post-translational modification of p53 
As previously mentioned p53 is a crucial cell regulatory protein which is constantly being 
synthesized so that it is ready to respond rapidly to cellular stresses (Kubbutat et al., 
1997). Therefore, p53 is highly regulated through various combinations of PTMs, with at 
least 50 different reported modifications including phosphorylation, methylation, 
acetylation, glycosylation, sumolyation, neddylation and poly-ribosylation (Figure 1.2) 
(Meek and Anderson, 2009). Many of these modifications have been found to be 
interdependent (Meek and Anderson, 2009).   
When p53 function is not required the E3 ligase mouse double minute 2 homologue 
(MDM2) polyubiquitinates p53 (Haupt et al., 1997). This polyubiquitination targets p53 
for proteasomal degradation (Haupt et al., 1997). When genotoxic stress is present 
MDM2 becomes inhibited through a number of mechanisms, including acetylation of p53 
(Tang et al., 2008). Once MDM2 is inhibited p53 levels rise dramatically (Bates and 
Vousden, 1996).  
The p53 protein is also inhibited by monomethylation on lysine 382 by the lysine 
methyltransferase Su(var)3-9, Enhancer of Zeste, Trithorax 8 (SET8) (Shi et al., 2007) 
and mono-methylation on lysine 370 by another lysine methyltransferase, lysine 
methyltransferase 3C (KMT3C) (Huang et al., 2006). Methylation at these sites inhibits 
p53’s transactivation activity. As mentioned above, p53 can be activated by 
phosphorylation of certain residues. The phosphorylation of p53 at Ser15 activates p53 
activity and has been found to promote further phosphorylation at other sites enhancing 
p53 translational activity (Yang et al., 2004). Notably, p53 can also be activated by 
methylation at lysine 372 by Su(var)3-9, Enhancer of Zeste, Trithorax 7/9 (SET7/9) 
(Chuikov et al., 2007). 
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Figure 1.2: Identified post-translational modifications of human p53 and their 
suspected modifying proteins. The p53 protein undergoes a number of post-translational 
modifications, including phosphorylation, methylation, acetylation, ubiquitination and 
glycosylation as shown here. A number of modifying proteins regulate these 
modifications which lead to p53 activation, inhibition, stabilization or destabilization. 
(Meek and Anderson, 2009) 
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1.2.4 Stabilization of p53 by Numb 
Numb was originally identified as a cell fate determinant in Drosophila embryos during 
the development of the Drosophila nervous system (Uemura et al. 1989). Ten years later, 
four human Numb isoforms were discovered (Verdi et al. 1999). Expression of Numb 
isoforms has been identified in almost all adult and embryo tissues, suggesting that Numb 
function is not specific to neuronal development.  
Numb has been characterized as an adaptor protein with a wide range of functions 
including roles in differentiation (Zhong et al., 1997), cell polarity and adhesion (Wang et 
al., 2009), cell migration (Nishimura and Kaibuchi, 2007), endocytosis (Santolini et al., 
2000) and ubiquitination and proteolytic degradation (McGill and McGlade, 2003). 
Numb interacts with its binding partners via two protein-protein binding domains, an 
amino terminal phosphotyrosine binding domain (PTB) (Bork and Margolis, 1995; Li et 
al., 1998;  Li et al., 1997) and a carboxy-terminal proline rich region (PRR) with Src- 
homology 3(SH3) binding sites (Yan, 2010). Also at the C-terminus, there are Esp15 
homology (EH) regions containing aspartic acid-proline-phenylalanine (DPF) and 
asparagine-proline-phenylalanine (NPF) motifs (Gulino et al., 2010). There have been 9 
splice variants identified to date, with isoforms 1-4 the most well-known. Isoform 1 and 3 
have predicted molecular weight of 72 and 71 kDa (Numb-PRRL) respectively and differ 
from isoform 2 and 4, with a molecular weight of 66 and 65 kDa (Numb-PRRS) 
respectively, by an insert of 48 amino acids within Numb’s proline rich region (PRR) 
(Yan, 2010). Isoform 1 and 2 also contain an 11 amino acid insert within the PTB domain 
which isoform 3 and 4 do not contain (Yan, 2010).  
Numb can form binary complexes with MDM2 and p53 (Numb-MDM2 and Numb-p53) 
(Juven-Gershon et al., 1998; Yogosawa, 2008) as well as a tricomplex with both MDM2 
and p53 (Numb-MDM2-p53) (Yogosawa, 2008). Numb binding to p53 stabilizes the 
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protein by inhibiting MDM2 polyubiquitination of p53, so that p53 is no longer targeted 
for degradation (Yogosawa, 2008). Critically, the Numb-p53 interaction has been shown 
to be regulated by Numb methylation (Dhami et al., 2013). In an unstressed cell, Numb 
has been shown to be methylated on lysine 158 (K158) and lysine 163 (K163) by the 
methyltransferase SET8 (Dhami et al., 2013). This methylation blocks Numb binding to 
p53 (Dhami et al., 2013). When the cell experiences a stress such as DNA damage, 
Numb will become demethylated allowing it to bind to and stabilize p53 (Dhami et al., 
2013). Numb bound p53 is then able to activate target genes required for the induction of 
apoptosis (Dhami et al., 2013) (Figure 1.3).  
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Figure 1.3: The working model of Numb demethylation which leads to stabilization 
of p53. The lysine demethylase SET8 has been found to methylate Numb. However when 
the cell experiences a stress signal such as excessive DNA damage or aberrant oncogene 
expression, an unidentified lysine demethylase (KDM) demethylates Numb. This 
demethylation allows Numb binding to p53. The binding of Numb to p53 inhibits MDM2 
polyubiquitination of p53 which leads to its proteasomal degradation. Stabilization of p53 
by Numb binding leads to the up-regulation of pro-apoptotic genes transactivated by p53, 
which lead to the induction of apoptosis. (Dhami et al., 2013) 
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1.3 The lysine demethylase PHF8 
1.3.1 The identification of PHF8 
Plant homeodomain finger containing protein 8 (PHF8) is a lysine demethylase 
(KDM). The PHF8 gene is located in the Xp11.21 chromosome (Laumonnier et al., 
2005). It was first identified in 2005 for its association with X linked mental 
retardation (XLMR) and cleft lip/ cleft lip palate (Laumonnier et al., 2005). A 
mutation in phenylalanine 279 of PHF8 to a serine (F279) is a common mutation seen 
in patients with XLMR (Koivisto et al., 2010). This F279S mutation is located within 
the catalytic domain of PHF8 and therefore causes the enzyme to have defective 
demethylase activity. Truncation mutations have also been identified in XLMR 
patients (Laumonnier et al., 2005; Abidi et al., 2007). Since PHF8 is largely a nuclear 
protein, it is thought that these truncating mutations delete putative nuclear 
localization sequences (NLS) therefore inhibiting PHF8 from entering the nucleus 
and acting on its target genes (Abidi et al., 2007). 
Although PHF8 is a ubiquitously expressed protein, murine PHF8 expression levels 
were found to be high in both the embryonic and adult brain of mice (Laumonnier et 
al., 2005). PHF8 has also been shown to be involved in neuronal differentiation (Qui 
et al., 2010). Exogenous overexpression of PHF8 in the mouse embryonic cell line 
P19 drove cells towards neuronal differentiation (Qui et al., 2010). At least one of the 
ways PHF8 drives neuronal differentiation is through the retinoic acid receptor alpha 
(RARα). PHF8 has been found to activate RARα expression as well as act as a co-
activator of RARα through direct interaction with the receptor (Qui et al., 2010).  
1.3.2 Characterization of PHF8 
The PHF8 protein is a lysine demethylase that belongs to the largest family of 
demethylases, the Jumonji C (JmjC) family also known as JmjC histone demethylases 
(JHDM) (Loenarz et al., 2009; Yue et al., 2010). Unlike other demethylases, JmjC 
domain containing proteins are able to remove all three histone methylation states, 
mono-, di- and tri-methylation (Klose et al. 2006). JHDMs catalyze lysine 
demethylation in an oxidative reaction and they require cofactors α- ketogluterate and 
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iron [Fe (II)] for the demethylation reaction as demonstrated in Figure 1.4A (Klose et 
al. 2006; Tsukada et al., 2006). Within the JHDM family, PHF8 belongs to the lysine 
demethylase 7 (KDM7) subfamily containing three members: KDM7A/JHDM1D, 
KDM7B/PHF8, and KDM7C/PHF2 (Fortschegger and Shiekhattar, 2011). All KDM7 
family members seem to target mono- and dimethylated histone H3 lysine 9 
(H3K9me1/2), dimethylated histone H3 lysine 27 (H3K27me2) and monomethylated 
histone H4 lysine 20 (H4K20me1) (Fortschegger and Shiekhattar, 2011). 
The PHF8 protein exists in at least 4 different isoforms created by alternate splicing. 
Isoform 1 is the largest, containing 1060 amino acids and weighing approximately 
118kDa (Kikuno et al., 1999). Isoform 2 of PHF8 is missing amino acids 1-36 and 
therefore contains 1024 amino acids (Bechtel et al., 2007). Isoform 3 is missing 
amino acids 478-578 and  isoform 4 is missing both amino acids 1-36 and 478-578 
but also has an additional 24 amino acids added to the C terminal of the protein (Ota 
et al., 2004). PHF8 contains a PHD zinc finger domain at amino acids 7-53 in isoform 
2 (Laumonnier et al., 2005) or 43-89 in isoform 1(Kikuno et al., 1999). The JmjC 
domain is located between amino acids 195-294 in isoform 2 (Laumonnier et al., 
2005) and 231-330 in isoform 1 (Kikuno et al., 1999). Both of these domains are 
highly conserved among PHF8 homologues in other species. PHF8 is a highly 
conserved protein though evolution with orthologues present in yeast (Laumonnier et 
al., 2005).  
The PHD domain of PHF8 is believed to recognize and bind to tri-methylated histone 
H3 lysine 4 (H3K4me3) (Figure 1.4B)(Feng et al., 2010). This binding localizes 
PHF8 to its target methylated lysines, giving it substrate specificity (Feng et al., 
2010). The targeting of PHF8 to H3K4me3 suggests that it is involved in promoting 
transcription as H3K4me3 is a suggested marker for gene activation. Methylated 
H3K27, H4K20 and H3K9 are all found to repress transcription (Vakoc et al., 2006). 
Since PHF8 removes these methylation marks it can be said that it is involved in 
transcriptional activation. Previous studies have also showed a direct interaction of 
PHF8 with the C-terminal domain of RNA polymerase II (PolII) (Fortschegger et al., 
2010). Both PHF8 and PolII have also been found to bind to Su(var)3-9, Enhancer of 
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Zeste, Trithorax 1 (SET1) (Liu et al., 2010; Ng et al., 2003). SET1 methylates H3K4 
(Roguev et al., 2001), therefore providing PHF8 with its binding site.  
Additionally, PHF8 has been found to be a regulator of the cell cycle, specifically in 
the promotion of the G2/ M transition (Lim et al., 2013). Lim et al., (2013) found the 
levels of PHF8 to be highest at both the G2 phase and the beginning of M phase. This 
study found that when PHF8 is knocked down, it results in delayed G2/ M phase 
transition and therefore impairs mitosis (Lim et al., 2013). Sun et al., (2013) 
discovered that when they knocked down PHF8 there was a decrease in cell 
proliferation, supporting PHF8’s involvement in promoting cell cycle progression. 
Phosphorylation of PHF8 by cyclin dependent kinase 1(CDK1) has been found to 
occur on serine 33 and serine 84 causing the dissociation of PHF8 from its bound 
chromatin (Liu et al., 2010). This phosphorylation and subsequent dissociation occurs 
towards the end of the G2 phase allowing accumulation of H4K20me1 and 
progression into mitosis (Liu et al., 2010). During interphase PHF8 is recruited to the 
chromatin again by its interaction with H3K4me3 (Liu et al., 2010).  
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Figure 1.4: The mechanism of PHF8 catalyzed demethylation reaction. A. The lysine 
demethylase PHF8 requires iron Fe (II) binding and α-ketogluterate as a cofactor for 
demethylation activity. The methyl group becomes oxidized forming an unstable 
hydroxymethyl (CH2OH). This hydroxymethyl group becomes released as formaldehyde 
(CH2O), (Klose et al., 2006). B. A ribbon model of PHF8 demonstrates binding to a 
H3K4me3K9me2 peptide (green stick structure). The H3K4me3 is interacting with the 
PHD domain (cream), while the H3K9me2 is interacting with the JmjC domain (indigo) 
along with the Fe (II) molecule (red sphere) and α-ketogluterate (yellow stick structure) 
(Krishnan et al., 2011). 
 
A 
B 
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1.3.3 Oncogenic properties of PHF8 
The PHF8 protein has recently been identified as an oncogenic protein (Bjorkman et 
al., 2012). Elevated PHF8 expression has been reported in many prostate cancer 
patient samples (Bjorkman et al., 2012). PHF8 has also been found to play a role in 
the pathogenesis of esophageal squamous cell carcinoma (ESCC) (Sun et al., 2013). 
PHF8’s oncogenic effects are a result of its ability to promote cell migration, cell 
cycle progression/cell proliferation and inhibit apoptosis (Bjorkman et al., 2012; Sun 
et al., 2013). 
PHF8 promotes cell motility by regulating cytoskeletal remodeling as well as up-
regulating the expression of genes involved in cell migration such as fibronectin, 
integrins and proteins involved in the integrin pathway (Bjorkman et al., 2012; 
Asensio-Juan et al., 2012). When PHF8 is silenced in prostate cancer cells there is a 
significant decrease in cell motility (Bjorkman et al., 2012). The opposite is seen 
when PHF8 is overexpressed, cells become more motile (Bjorkman et al., 2012). Sun 
et al., (2013) also found that PHF8 knockdown ESCC cells were more motile and 
invasive then their PHF8 expressing counterparts.   
As an example of its oncogenic roles, PHF8 has also been found to promote cancer 
cell proliferation. Knockdown of PHF8 significantly decreased cell proliferation in 
prostate cancer cells (Bjorkman et al., 2012). One of the ways PHF8 is suggested to 
affect cell cycle progression is through the demethylation of H4K20 (Liu et al., 
2010). Methylated H4K20 is a repressive mark found on many of the oncogenic 
transcription factor E2F, target genes (Abbas et al., 2010), and PHF8 binds to E2F1 
(Liu et al., 2010). PHF8 has also been found to promote cell proliferation in 
esophageal squamous carcinoma cells (Sun et al., 2013). Sun et al., (2013) reported 
that when they knocked down PHF8 they saw significant inhibition of cell 
proliferation. They also found that both anchorage- dependent and independent 
growth of ESCC cells were decreased when PHF8 was knocked down (Sun et al., 
2013). This same study also reported that when prostate cancer cells were injected 
into nude mice they formed larger tumours than those injected with prostate cancer 
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cells with PHF8 knocked down by shRNA (Sun et al., 2013). This suggests that 
PHF8 may be a potential target for cancer therapeutics. 
Finally, an effect of PHF8 on apoptosis has also been identified. Bjorkman et al., 
2012 report a weak yet significant effect on apoptosis in cells with PHF8 knocked 
down. Knockdown of PHF8 in ESCC cells was also found to significantly increase 
apoptosis (Sun et al., 2013). Although PHF8 has been found to negatively affect 
apoptosis, there has been no research done to investigate the mechanism behind its 
anti-apoptotic effect.  
 
1.4 The purpose of this thesis 
It is known that Numb is methylated by SET8 at sites K158 and K163; however the 
protein responsible for demethylating Numb remains unknown. The purpose of this 
thesis was to determine which lysine demethylase is demethylating Numb. We 
identified PHF8 as a possible candidate for the Numb demethylase since it targets 
methylated H3K27 and H4K20 which share sequence similarities to Numb K159 and 
K163 (Dhami et al., 2013). Previous research has indicated PHF8 as an oncogene; 
therefore it would be of interest to further investigate any possible roles for the lysine 
demethylase in regulating p53 mediated apoptosis. 
We hypothesize that PHF8 demethylation activity plays a regulatory role in the 
intrinsic p53-mediated apoptosis pathway. 
 
Aim 1: Identify and characterize candidate Numb demethylases 
 
To address this aim we selected possible demethylases by identifying demethylases 
known to target lysines on histone tails with similar surrounding sequences to Numb 
K158 and K163. The chemotherapeutic drug, doxorubicin, was used to induce 
apoptosis and the levels of mRNA of these demethylases were observed during 
apoptosis to see if there were any changes compared to non-apoptotic/ untreated cells. 
SET8 levels have been found to decrease when cells undergo apoptosis, so we 
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suspected that the potential Numb demethylase levels would increase when apoptosis 
is induced. 
 
 
Aim 2: Observe the effect of PHF8 on apoptosis  
 
To address this second aim, flow cytometry analysis was done to observe the effect of 
PHF8 on apoptosis. PHF8 was either overexpressed or knocked down and the levels 
of apoptosis were observed. Quantitative real time-PCR (qRT-PCR) was used to 
observe any effect PHF8 has on genes involved in apoptosis. The mRNA levels of the 
apoptotic proteins were observed in cells with PHF8 overexpressed and in cells with 
PHF8 knocked down. Chromatin immunoprecipitation (ChIP) was also done to 
determine if PHF8 is directly regulating the promoters of the observed apoptotic 
genes it seemed to have an effect on. ChIP analysis was also done with H3K27me3 
immunoprecipitated from cells overexpressing PHF8 and cells with PHF8 knocked 
down, to determine if PHF8 was regulating the genes through the methylation status 
of H3K27. 
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Chapter 2  
2 Materials and Methods  
2.1 Solutions and buffers 
All solutions and buffers used are listed here in table 2.1.  
Table 2.1: Solutions and buffers 
Solution Components  
1×TAE buffer (pH8.5)  Tris base 40 mM, EDTA 1 mM, Glacial acetic acid 
adjusting pH to 8.5  
 
1× TBST  Tris base 20 mM, NaCl 137 mM, Tween20 0.05% (v/v)  
 
1× PBS buffer  KH2PO4 1 mM, Na2HPO4 10 mM, KCl 2.7 mM, NaCl 137 
mM  
 
5× SDS-PAGE 
(Laemmli) Sample 
buffer  
Tris base (pH 6.8) 312 mM, SDS 10%, α-mercaptoethanol 
25%, Bromophenol Blue 0.05%, Glycerol 50%  
 
Western blot transfer 
buffer  
Methanol 20%, 24 mM Tris base, 194 mM Glycine  
 
1x MOPS buffer  
50 mM MOPS, 50 mM Tris base, 0.1%  SDS, 1 mM EDTA 
 
ChIP SDS lysis buffer 1% SDS, 10 mM EDTA, 50 mM Tris (pH 8.1) 
ChIP dilution buffer 0.01% SDS, 1% Triton X-100, 1.2 mM EDTA, 16.7 mM 
Tris-HCL (pH 8.1), 167 mM NaCl 
LiCl wash 0.25 M LiCl, 1% IGEPL-CA630, 1% deoxycholic acid 
(sodium salt), 1mM EDTA, 1 mM Tris (pH8.1) 
High salt wash 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCL (pH8.1), 500 mM NaCl 
Low salt wash 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCL (pH8.1) 
TE pH 8.0 10 mM Tris-HCl, 1 mM EDTA (pH adjusted with HCl) 
 
19 
 
2.2 Cell culture, transfection and siRNA knock down 
2.2.1 Cell culture 
HeLa cells a cervical cancer cell line and U2OS cells, an osteosarcoma cell line, were 
grown in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum (FBS) and 2 
mg/ml glutamine at 37 ℃ with 5% CO2. 
2.2.2 Cell transfection 
Cells were subcultured the day prior to the transfection to be 50-80% confluent in a 100 
mm tissue culture dish. 8 µg of DNA was mixed with 440 µl warm Opti-MEM (Life 
Technologies) and incubated at room temperature for 5 minutes. 60 µl (1 mg/ml) warm 
Polyethylenimine (PEI) was then added to the diluted DNA and mixed immediately for 
15 seconds. The solution was left for 20 minutes at room temperature prior to adding it to 
the cells. Before the addition of DNA to the cells, cells were washed three times with 
warm 1 x phosphate buffered saline (PBS) and cells were left in 4.5 mL antibiotic free 
media. 24 hours after the addition of the DNA solution to the cells, cells were washed 
three times with warm 1 x PBS and 10 mL of fresh media was added to the plate. Cells 
were then grown for another 18-24 hours prior to use. 
2.2.3 SiRNA transfection 
Cells were subcultured the day prior to the transfection to be 40-70% confluent. 10 µl of 
100 µM siRNA (Sigma-Aldrich) was diluted in 990µl serum free media and incubated at 
room temperature for 5 minutes. 20 µl DharmaFECT (ThermoFisher Scientific, 
Catalogue #T-2001-01) was diluted in 980 µl serum free media and also incubated at 
room temperature for 5 minutes. The two were then mixed together and incubated at 
room temperature for 20 minutes. Cells were washed three times with 1 x PBS then 
replenished with 8 ml of antibiotic free media. The siRNA mixture was then added to the 
cells and incubated at standard conditions for 48 hours.   
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2.2.4 Doxorubicin treatment 
Cells were treated with 1 µM doxorubicin hydrochloride (Sigma-Aldrich, Catalogue # 
D1515-10MG) dissolved in ddH2O for 18 hours at 37°C. Doxorubicin was added directly 
to cell culture media. For a 100 mm dish with 10 ml of media, 2 µl of 5 mM doxorubicin 
stock was used. 
2.3 Quantitative real-time polymerase chain reaction (qRT-PCR) 
2.3.1 TRIzol RNA isolation 
Cells were grown in 6-well dishes, 2 wells per condition. Cells were transfected on day 
one, media changed and doxorubicin was added on day 2 for an 18 hour treatment. Media 
was aspirated and 600 µl of TRIzol (Life Technologies, Catalogue#15596-026) was 
added per well. Cells were scraped off the dish in TRIzol and collected in micro-
centrifuge tubes and the mixture was pipetted up and down a few times. Cells were left at 
room temperature for 5 minutes prior to the addition of 120 µl chloroform. Tubes were 
shaken vigorously for 15 seconds and left at room temperature for 3 minutes. Samples 
were then centrifuged for 15 minutes at 4°C at 12 000 x g. The upper aqueous phase was 
transferred to a new centrifuge tube and 300 µl isopropanol was added and left at room 
temperature for 10 minutes to precipitate the RNA. The precipitated RNA was the 
pelleted by centrifugation 12 000 x g for 10 minutes at 4°C. The RNA pellet was then 
washed with 1 mL 75% ethanol and centrifuged again for 5 minutes 12 000 x g at 4°C. 
The ethanol was aspirated away and the pellet was left to air dry for 5 to 10 minutes. The 
RNA was re-suspended in DEPC treated water (RNase-free) by pipetting up and down 
several times and incubating 15 minutes in a 55°C water bath. RNA concentration was 
calculated by measuring absorbance A260 and using the following formula 
                  
     
  
. Absorbance at A280 was also measured and the ratio 
A260/A280 was calculated to ensure a ratio >1.8. Samples were either stored at -80°C or 
used for cDNA synthesis for qPCR. 
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2.3.2 cDNA synthesis 
Isolated RNA was reverse transcribed since cDNA is more stable than RNA. BioRad’s 
iScript
TM
 Reverse Transcription Supermix for RT-qPCR was used (Bio-Rad, Hercules, 
CA, Catalogue # 170-8840). 500 ng-1 µg of RNA was used depending on the 
concentration of each sample. For each set of experiments the RNA concentration was 
adjusted so all samples were at the same concentration. 2 µl of RNA solution was added 
to 4 µl 5x iScript reverse transcription supermix (Bio-Rad, Hercules, CA, Catalogue # 
170-8840) and14 µl of water for a final volume of 20 µl for each sample. The reaction 
mixtures were prepared in PCR tubes. In a PCR thermocycler (iCycler- Biorad, Hercules, 
CA) the following protocol was used for cDNA synthesis: 5 minutes at 25°C, 30 minutes 
at 42°C, 5 minutes at 85°C and a final hold at 4°C. A no-RT control was also done to 
exclude genomic DNA contamination. 
2.3.3 qRT-PCR procedure 
iQ
TM
 SYBR
®
 Green Supermix (Bio-Rad, Hercules, CA, Catalogue # 170-8884) was used 
for RT-qPCR reactions performed in the Bio-Rad CFX connect Real-Time system (Bio-
Rad, Hercules, CA). iQ
TM
 SYBR
®
 Green Supermix contains iTaq DNA polymerase, 
dNTPs, MgCl2, SYBR
®
 Green I dye, fluorescein as well as enhancers and stabilizers. 
Each reaction was a final volume of 10 µl consisting of 4 µl cDNA and 0.2 µl forward 
primer, 0.2 µl reverse primer, 0.6 µl nuclease free H20, 5 µl SYBR Green supermix. The 
forward and reverse primers, nuclease-free H2O and SYBR Green were combined into a 
master mix and 6 µl of mater mix was added to the cDNA. The reactions were carried out 
with the following parameters: 
 Cycle 1: Denaturation: 95°C 3 minutes  
 Cycle 2 (40-50 x):  Denaturation: 95°C 10 seconds  
  Annealing/extension: 60°C 30 seconds 
 Finally samples were heated from 65°C to 95°C in 0.5°C increments every 5 seconds to 
create a melt curve. Further analysis such as normalization, graphs and statistics were 
done using Microsoft Excel.   
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2.3.4 qRT-PCR primers 
Primers used in this study for qPCR analysis were designed using the National Center for 
Biotechnology Information’s (NCBI) Primer-BLAST search and ordered from Sigma 
Aldrich. The sequences for the primers used can be found in Table 2.2. 
Table 2.2: List of qRT-PCR primers 
Gene Forward primer Reverse primer 
SETD8 GGGGAAACCATTAGCCGGAA TGTTCCTCGGACTTCATGGC 
KDM6B TGAAGAACGTCAAGTCCATTG TCCCGCTGTACCTGACAGT 
KDM6A ATGGAAACGTGCCTTACCTG ATTAGGACCTGCCGAATGTG 
PHF8 TAGCACAGGGCACAAGGTTC CGATAGGCTGGGCTCTTTCC 
TP53 GAGGTTGGCTCTGACTGTACC TCCGTCCCAGTAGATTACCAC 
BAX TTTGCTTCAGGGTTTCATCC CAGTTGAAGTTGCCGTCAGA 
CASP3 TGAGGCGGTTGTAGAAGAGTT TGAACCAGGAGCCATCCTTT 
PUMA GCCAGATTTGTGAGACAAGAG
G 
CAGGCACCTAATTGGGCTC 
Rpl13 GCCCTACGACAAGAAAAAGCG TACTTCCAGCCAACCTCGTGA 
GAPDH 
(ChIP) 
CAATTCCCCATCTCAGTCGT 
Nucleotides region 467-482 
TAGTAGCCGGGCCCTACTTT 
Nucleotides region 654-673 
BAX  
(ChIP) 
TTTGCTTCAGGGTTTCATCC 
Nucleotides region 144-163 
CAGTTGAAGTTGCCGTCAGA 
Nucleotides region 370-389 
TP53 
(ChIP) 
CAGCACATGACGGAGGTTGT 
Nucleotides region 562-581 
TCATCCAAATACTCCACACGC 
Nucleotides region 666-686 
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CASP3 
(ChIP) 
TGAGGCGGTTGTAGAAGAGTT 
Nucleotides region 65-85 
TGAACCAGGAGCCATCCTTT 
Nucleotides region 890-909 
 
2.4 Transformation of Escherichia coli (E. coli) and DNA 
plasmid amplification 
500 ng – 1 µg of plasmid DNA (Table 2.3) was added to a microcentrifuge tube on ice. E. 
coli DH5α cells were thawed on ice. 30 µl of the competent cells were added to the DNA 
and mixed by gently pipetting up and down several times. The cells and DNA were 
incubated on ice for 15 minutes. The bacteria/plasmid mixture was then heat shocked at 
42°C for 60 seconds, followed by incubation for 2 minutes on ice. 70 µl of antibiotic free 
LB media was added to the bacteria and plasmid mixture and was incubated at 37°C on a 
shaker for one hour.  
DH5α cells were then plated on agar plates with the appropriate antibiotic resistance. 
pFLAG-CMV constructs confer ampicillin resistance, therefore 50 μg/ml ampicillin agar 
plates were used. Plates of bacteria were left to grow overnight at 37°C. The next day 
colonies were picked and grown in 3 ml LB media with the appropriate antibiotic. Cell 
cultures were left to grow overnight at 37°C on a shaker.  
Plasmid DNA was purified using a miniprep DNA plasmid purification kit (Sigma-
Aldrich, St. Louis, MO, USA).  
Table 2.3: List of plasmids 
Plasmid Protein Host Source 
pFLAG-CMV2 Empty vector 
with FLAG tag 
E.coli 
DH5α 
Li lab 
pFLAG-
hPHF8-CMV2 
Human PHF8 
isoform 2 
E.coli 
DH5α 
Li lab (Courtney Voss); The ORFeome 
Collaboration (hPHF8 insert) 
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2.5 Cell extract preparation, immunoprecipitation and western 
blot 
2.5.1 Cell lysis 
Cells were placed on ice and washed three times with ice cold 1 x PBS. 500 µl-1 mL lysis 
buffer (Table 2.1) supplemented with 1 mM sodium orthovanadate, 2 μg/ml aprotinin, 10 
μM leupeptin, 1 μM E64, 1 μM bestatin, 1 μM pepstatin A and 1 mM 
phenylmethanesulfonyl fluoride (PMSF) was added to the 100 mm dish of cells and left 
on ice for 5 minutes. Cells were then scraped into a 1.5 ml Eppendorf tube using a rubber 
policeman on ice. The cell lysates were rotated for 15 minutes at 4°C prior to 
centrifugation at max speed (16000 x g) for 20 minutes at 4°C.  The supernatant was 
removed and used for subsequent experiments. 
2.5.2 Measurement of protein concentration 
Protein concentration was measured using Bradford dye assay (Bio-Rad protein assay). 
The dye was diluted in a 1 part dye to 4 parts ddH20 ratio. 1-2 μl of sample was added to 
800µl of diluted dye in a plastic cuvette. The absorbance was measured in a 
GENESYSTM spectrophotometer (Spectronic Unicam, Rochester, NY, USA) at a 
wavelength of 595 nm. Protein concentration of the sample was determined using a 
bovine serum albumin (BSA) standard curve. 
2.5.3 Measurement of DNA and RNA concentration 
5 μl of DNA or RNA sample was added to 495 µl ddH20 in a glass cuvette. 500 μl ddH20 
was used as a blank. Both DNA and RNA samples were measure at 260 nm absorbance. 
DNA concentration was calculated using the formula:                     
     
  
. 
RNA concentration was calculated using the formula:                    
     
  
. 
Absorbance was also read at 280 nm to get the 260 nm/280 nm ratio. 
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2.5.4 Immunoprecipitation (IP) 
To pre-clear the cell lysate 3 µg of anti-rabbit IgG was added to 1 mg total protein cell 
lysate. 40 μl of a 1:1 ratio mixture of protein A agarose beads (made in lab) to lysis buffer 
was added to the cell lysate with anti-IgG and incubated for one hour at 4°C on a shaker. 
Samples were centrifuged at 4°C 3000 x g for 5 minutes and the supernatant was 
transferred to a new 1.5 ml Eppendorf tube.  
3 µg of antibody for IP per 1 mg of total protein was then added to the pre-cleared lysate 
and incubated at 4°C on a shaker for 4 hours or overnight. 40 µl of protein A bead slurry 
in lysis buffer was added to each sample and incubated another hour at 4°C on a shaker. 
Samples were then centrifuged for 5 minutes 3000 x g at 4°C. Supernatant was removed 
and beads with the antigen and protein attached were washed three to five times with cell 
lysis buffer. After the last wash, supernatant was removed and 2 x SDS Laemmli sample 
buffer was added to the beads to elute the protein. 
2.5.5 Western blot (WB) 
20-40 µg of protein sample was loaded onto a 8-12 % Bis-Tris gel. Gels were run in 1 x 
3-(N-morpholino) propanesulfonic acid (MOPS) buffer (Table 2.1) at 110 V for 
approximately one to two hours. The separated proteins were then transferred onto a 
polyvinylidene fluoride (PVDF) membrane solubilized in methanol. A semi-dry blot 
transferring system (BioRad, Hercules, CA) was used to transfer the gel at 21 V for 30 
minutes. The gel and PVDF membrane were placed between two filter papers soaked in 1 
x transfer buffer (Table 2.1).  
Following the transfer, PVDF membranes were blocked in either 5 % skim milk in 1 x 
Tris-buffered saline with Tween (TBST) or 3%  bovine serum albumin (BSA) in 1 x 
TBST for one hour at room temperature  on a shaker. The blocking buffer was removed 
and the membrane was incubated with primary antibody diluted in blocking buffer for 
one hour on a shaker at room temperature or overnight at 4°C on a shaker. The dilution of 
primary antibody used was in accordance to the recommended dilution given by the 
manufacturer (Table 2.3).  
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After the primary antibody was removed, the membrane was rinsed three times with 1 x 
TBST then washed 3 x 5 minutes with 1 x TBST. Next the membrane was incubated in 
secondary antibody conjugated with horseradish peroxidase (HRP) diluted in a ratio of 
1:5000 in 5% skim milk in 1 x TBST for one hour. The membrane was then rinsed three 
times and washed 3x 15 minutes with 1 x TBST. An enhanced chemiluminescence (ECL) 
detection solution (GE Healthcare Life Sciences) was added to the membrane and 
incubated for 5 minutes. Excess ECL solution was removed and signals were exposed 
onto X-ray film over a range of 15 seconds to 15 minutes. Film was then developed using 
a Kodak M35A X-OMAT processor. 
Table 2.4: List of antibodies 
Antibody Species Source Conditions 
Numb (H-70) rabbit Santa Cruz Biotech 
(Catalogue number: sc-
25668) 
1:1000 dilution in 5% 
milk in 1xTBST 
PHF8 (ab36068) rabbit Abcam (Catalogue 
number:ab36068) 
1:1000 dilution in 5% 
milk in 1xTBST 
p53(DO-1) mouse Santa Cruz Biotech 
(Catalogue number: sc-126) 
1:1000 dilution in 5% 
milk in 1xTBST 
β-tubulin (H-235) rabbit Santa Cruz Biotech 
(Catalogue number: sc-
9104) 
1:1000 dilution in 5% 
milk in 1xTBST 
FLAG (M2) mouse Sigma Aldrich (Catalogue 
number: F3165) 
1:1000 dilution in 5% 
milk in 1xTBST 
Pan-lysine mono- 
and di- methylation 
rabbit Abcam (Catalogue number: 
ab23366) 
1:1000 dilution in 3% 
BSA in 1xTBST 
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H3K27me3 mouse Abcam (Catalogue number: 
ab6002) 
N/A 
 
2.6 Flow cytometry analysis 
Cells were plated on day 0, transfected with pFLAG-PHF8-CMV or pFLAG-CMV empty 
vector on day 1, media changed and treated with doxorubicin or not on day 2. On day 3 
cells were rinsed with 1 x PBS and trypsinized to remove the cells from the dish. The 
cells were collected and centrifuged at 1000 x g for 5 minutes and the supernatant 
removed. An Annexin V-FITC apoptosis detection kit (BioVision incorporated, Cat. # 
K101-100) was used to detect apoptotic cells according to the manufacturer’s protocol. 
Cells were re-suspended in binding buffer at a concentration of approximately 5x10
5
 
cells/ 500 µl. Cells were then passed through a cell strainer to prevent large clumps of 
cells from clogging the machine. 5 µl of each Annexin V-FITC and propidium iodide (PI) 
were added to each experimental sample and incubated at room temperature for 10 
minutes before being placed on ice. Control tubes were also set up containing no dye, PI 
alone Annexin V-FITC alone, and both PI and Annexin V-FITC. An unstained non-
doxorubicin treated sample was also used to observe the effect of doxorubicin on the 
emission spectra. 
Cells were analyzed on the LSRII flow cytometer (BD Bioscience) using FACS Diva 
software (BD Bioscience) in Robarts Research Facility. AnnexinV FITC samples were 
excited by the 488 nm blue laser and detected by the 530/30 detector. For PI stained cells 
the yellow-green 561 nm laser was used to excite samples and the 610/20 detector was 
used to detect the fluorochromes. Data analysis was done using FlowJo software (FlowJo 
Enterprise) and Microsoft Excel.  
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2.7 Chromatin immunoprecipitation (ChIP) assay 
Cells were plated on day 0, transfected with pFLAG-PHF8-CMV or pFLAG-CMV empty 
vector on day 1, media changed and treated with doxorubicin or vehicle ddH2O on day 2. 
On day 3, 270 µl of 37% formaldehyde was added to each 100 mm dish of cells 
containing 10 ml of media. Cells were incubated with the formaldehyde on a shaker at 
room temperature for 10 minutes to allow cross-linking of chromatin bound proteins to 
the nucleotides. 687.5 µl of 2 M glycine was added to the media to quench the cross-
linking. The medium mixture was them removed and cells were washed with cold 1 x 
PBS containing protease inhibitors. 1 ml of cold 1 x PBS plus protease inhibitors was 
added to the cells and scraped into microcentrifuge tubes. Cells were centrifuged at 3000 
x g at 4°C for 5 minutes. Supernatant was removed and the cell pellet was re-suspended 
in 200 µl ChIP lysis buffer (Table 2.1). Cells were incubated at room temperature for 5 
minutes prior to being put on ice. 1.2 ml ChIP dilution buffer (Table 2.1) was added to 
each sample. Next the lysed cells were sonicated (60 Sonic Dismembrator, Fisher 
Scientific) for 5 x 15 second on 45 seconds off pulses on number 5. 40 µl of a mixture of 
0.2 mg/ml sheared salmon sperm DNA (ssDNA) in ChIP dilution buffer and protein G 
sepharose beads at a 1:1 ratio was added to the lysate and incubated at 4°C on a nutator to 
pre-clear the sample. Samples were centrifuged for 2 minutes at 3000 x g 4°C and 
supernatant transferred to new tubes. 100 µl of supernatant was saved from each sample 
for ChIP input DNA for normalization. 3 µg of antibody was added to the samples and 
incubated overnight on a nutator at 4°C. 40 µl of Protein G sepharose/ ssDNA bead slurry 
was added to each sample and incubated at 4°C for 1 hour on a nutator. Samples were 
centrifuged 4 minutes at 3000 x g at 4°C. Supernatant was removed and beads were 
washed with 1 ml low salt buffer (Table 2.1) for 30 minutes, then high salt buffer (Table 
2.1) for 15 minutes, then LiCl buffer (Table 2.1) for 10 minutes. Each of these washes 
was at 4°C on a nutator with centrifugation at 3000 x g at 4°C between to remove each 
wash. The final two washes were in TE buffer (pH 8.0) (Table 2.1) at room temperature 
for 5 minutes each. The sample was eluted off the beads using 100 µl 1% SDS and 0.1 M 
NaHCO3 in ddH2O. Samples were incubated on a shaker at room temperature for 4 hours 
then centrifuged for 1 minute at 3000 x g and supernatant kept. Elutant was incubated at 
65°C overnight to de-crosslink DNA along with the ChIP input samples.  
29 
 
DNA was purified from the sample using QIAEX II Gel Extraction kit (Qiagen, Venlo, 
Limburg, Netherlands, Catalogue #20021) following the manufacturer’s protocol to 
extract DNA from solutions. DNA fragments were analyzed using qRT-PCR.  
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Chapter 3  
3 Results 
3.1 Prediction of possible Numb demethylases 
The original goal of this study was to identify the lysine demethylases responsible for 
demethylating Numb. Numb has been shown to be methylated by the lysine 
methyltransferase SET8 on lysine residues K158 and K163 (Dhami et al., 2013). The first 
step in identifying SET8 as the possible lysine methyltransferase targeting Numb was to 
look at the peptide sequence surrounding the two methylation sites (Dhami et al., 2013). 
Dhami et al., 2013 preformed a sequence alignment and found that the sequence was 
closely related to histone H3 lysine 27 (H3K27) and histone H4 lysine 20 (H4K20), as 
well as the p53 lysine 382 (p53K382) methylation site (Dhami et al., 2013). The latter 
two are known targets of SET8 (Nishioka et al., 2002; Shi et al., 2007). Table 3.1 shows 
the protein sequences surrounding the lysines of interest targeted for methylation. 
Since H3K27 and H4K20 were found to have similar surrounding sequences to those of 
the Numb K158 and K163 residues (Dhami et al., 2013), we narrowed down the possible 
lysine demethylase by identifying demethylases known to target H3K27 and H4K20. We 
decided to investigate lysine demethylase 6B (KDM6B) and lysine demethylase 6A 
(KDM6A) which both demethylate H3K27 (Lan et al., 2007; Hong et al., 2007). In 
addition to the KDM6 demethylases, plant homeodomain (PHD) finger containing 
protein 8 (PHF8) which is known to demethylate monomethylated H4K20 (Lui et al., 
2010) and dimethylated H3K27 (Loenarz et al., 2010) was also investigated.  
3.2 PHF8 expression increases during doxorubicin induced 
apoptosis 
In order to test which of the suspected lysine demethylases may be demethylating Numb 
we first looked at which of those demethylases are elevated during apoptosis. The Numb 
methyltransferase, SET8, has previously been found to be down regulated in cells 
undergoing apoptosis (Dhami et al., 2013), therefore we suspected that the possible 
Numb demethylase would be up-regulated when apoptosis is induced. Quantitative real  
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Table 3.1: Sequence comparison of Numb lysine methylation sites to histones and 
p53 methylation sites. H3K27 and H4K20 were previously identified by sequence 
alignment to have similar sequence similarity of residues surrounding the methylated 
lysine as Numb K158 and K163. The methylated lysine K382 of p53 was also identified 
to have a similar sequence to both Numb methylation sites, H3K27 and H4K20. The 
alignment gave a score to each of the lysine residues based on sequence similarity of the 
surrounding amino acids compared to those of Numb (K158). (Dhami et al., 2013) 
Protein Sequence containing lysine methylation site Alignment 
Score 
hNumb 143-HAVGCAFAACLERKQKREKECGVTATFDAS-174 N/A 
H4K20 1-GRGKGGKGLGKGGAKRHRKVLRDNIQGITKPA-34 2.5 
p53K382 363-HSSHLKSKKGQSTSRHKKLMFKTEGPDSD-393 1.5 
H3K27 10-TGGKAPRKQLATKAARKSAPATGGVKKPH-40 1.5 
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time polymerase chain reaction (qRT-PCR) was used to identify elevated lysine 
demethylases. U2OS cells were either untreated or treated with 1.0µM doxorubicin for 18 
hours to induce apoptosis. Cells were lysed and the total mRNA was extracted. PUMA, a 
protein involved in p53 mediated apoptosis was also selected as a positive control since 
its expression is known to increase when treated with doxorubicin (Dhami et al., 2013). 
SET8 was observed as a negative control since it has been found to decrease with 
doxorubicin treatment (Dhami et al., 2013).  
As shown in Figure 3.1, the levels of KDM6A remained relatively constant with the 18 
hour doxorubicin treatment compared to the untreated cells. The level of KDM6B mRNA 
however, decreased significantly with doxorubicin treatment. The only lysine 
demethylase tested whose levels increased significantly was PHF8. As expected, PUMA 
levels increased with doxorubicin treatment, well SET8 levels of mRNA decreased. 
To further confirm the observed increase in PHF8 expression during apoptosis, we 
repeated the experiment in HeLa cells (Figure 3.2). Once again the levels of PHF8 were 
significantly elevated with 18 hours of doxorubicin treatment compared to untreated 
cells. SET8 was used again as a negative control, which was significantly decreased in 
both cell lines. 
Although the mRNA levels of a gene may be elevated, it does not always result in 
elevated protein levels. Therefore our next step was to observe the protein expression 
level of PHF8 with doxorubicin treatment. To test this, cells lysates of both HeLa and 
U2OS cells treated with doxorubicin for 6 hours, 18 hours or left untreated, were 
analyzed by western blot (Figure 3.3). Both cell lines showed an increase in PHF8 
expression level at 18 hours compared to untreated cells (Figure 3.3, top panels). Numb 
and p53 expression levels were also observed. Both Numb and p53 expression levels also 
increased in both cell lines with doxorubicin treatment (Figure 3.3, middle panels). 
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Figure 3.1: Transcript expression levels of lysine demethylases with doxorubicin 
treatment. Total mRNA was extracted using TRIzol, from U2OS cells treated with 
1.0μM doxorubicin for 18 hours. The mRNA was reverse transcribed into cDNA. 
Primers targeting lysine demethylases were used to analyze levels of demethylase 
mRNA. SET8 was used as a negative control and PUMA was used as a positive control. 
Data presented is the mean ± SEM of three biological repeats. *- indicates significant 
difference from the corresponding control (p<0.05). 
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Figure 3.2: Transcript expression of PHF8 increased with doxorubicin treatment in 
both HeLa cells and U2OS cells. Total mRNA was extracted using TRIzol, from U2OS 
cells treated with 1.0 μM doxorubicin for 18 hours or from untreated cells. The mRNA 
was reverse transcribed into cDNA. Primers targeting PHF8 and SET8 were used to 
analyze levels of mRNA using qPCR.  Values were normalized to Rpl13. Data presented 
is the mean ± SEM of three biological repeats. *- indicates significant difference from the 
corresponding control (p<0.05). 
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Figure 3.3: PHF8 protein expression level was up-regulated with doxorubicin 
treatment for 18h. Both HeLa cells and U2OS cells were either left untreated or treated 
with 1.0µM doxorubicin for 6 hours or 18 hours. Cells were lysed and samples were 
separated using an 8% Bis-Tris gel. Western blot analysis was done using anti-PHF8 
(upper panel), anti-Numb (second panel), anti-p53 (third panel) and anti-β-tubulin 
(bottom panel). β-tubulin was observed as a loading control to ensure equal levels of 
protein were added.   
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3.3 PHF8 does not demethylate Numb 
The significant increase in PHF8 mRNA (Figure 3.1 and Figure 3.2) and protein levels 
during apoptosis (Figure 3.3) led us to believe it could be the demethylase responsible for 
demethylating Numb. To further test this prediction we set out to observe whether or not 
PHF8 has an effect on Numb methylation. To do this we overexpressed pFLAG-PHF8-
CMV or pFLAG-CMV empty vector in HeLa cells and immunoprecipitated endogenous 
Numb. Cells were either treated with 1.0µM doxorubicin or left untreated. Numb 
immunoprecipitated samples along with cell lysates were observed using SDS-PAGE and 
western blot analysis. As seen in Figure 3.4 A, PHF8 appears to have no effect on Numb 
methylation status.  
3.4 PHF8 has an anti-apoptotic function 
Since PHF8 expression increases with doxorubicin induced apoptosis, we predicted that 
PHF8 would promote apoptosis. To test this hypothesis we used flow cytometry analysis. 
We first observed cells with PHF8 knocked down using siRNA specific to PHF8. As a 
control we also observed cells transfected with a scrambled control siRNA. Cells were 
treated with 1.0 µM doxorubicin for 18 hours or left untreated. Cells were analyzed using 
Annexin V FITC to observe cells in early apoptosis and propidium iodide (PI) was used 
to analyze cells in late apoptosis. A significantly higher percentage of cells with PHF8 
knocked down were undergoing apoptosis when treated with doxorubicin compared to 
cells containing the scrambled control siRNA (Figure 3.5). Even untreated PHF8 
knockdown cells showed slightly more apoptosis than control cells, however this was not 
significant.  
To further confirm that PHF8 promotes cell survival, HeLa cells were transfected with 
FLAG tagged PHF8 to observe how PHF8 overexpression affected apoptosis. Cells were 
also transfected with the empty vector pFLAG-CMV as a control. Again cells were 
stained with Annexin V FITC and PI and analyzed using flow cytometry to detect 
apoptotic cells. As expected, cells overexpressing PHF8 were significantly less apoptotic 
compared to cells transfected with empty vector pFLAG-CMV (Figure 3.6). There was  
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Figure 3.4: PHF8 does not demethylate Numb. HeLa cells were transfected with 
FLAG-PHF8 or pFLAG-CMV and treated with 1.0µM doxorubicin for 18 hours or left 
untreated. Cells were lysed and endogenous Numb was immunoprecipitated with anti-
Numb antibody. The immunoprecipitate (A) and cell lysate (B) were run on 8% Bis-Tris 
SDS-PAGE and analyzed by western blot. Immunoprecipitate blots were blotted with 
anti-Numb and a pan-methylation antibody (A). Lysate blots were blotted with anti-
FLAG, anti-PHF8, anti-Numb, anti-p53 and anti-β-tubulin (B). 
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Figure 3.5: Cells transfected with siRNA against PHF8 undergo more apoptosis 
when treated with doxorubicin. HeLa cells were transfected with either siRNA against 
PHF8 or a scrambled control siRNA. Cells were treated with 1.0μM doxorubicin for 18 
hours or left untreated. Annexin V FITC and propidium iodide were used to select for the 
apoptotic cells within the population. Apoptotic cells were identified using flow 
cytometry analysis. Data presented is the mean ±SEM of five biological repeats. *- 
indicates significant difference from the corresponding control (p<0.025). 
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Figure 3.6: Cells overexpressing PHF8 undergo similar apoptosis as control cells 
when treated with doxorubicin. HeLa cells were transfected with either FLAG-PHF8 or 
pFLAG-CMV. Cells were treated with 1.0μM doxorubicin for 18 hours or left untreated. 
Annexin V FITC and PI were used to select for the apoptotic cells within the population. 
Apoptotic cells were identified using flow cytometry analysis. Data presented is the mean 
±SEM of six biological repeats. *- indicates significant difference from the corresponding 
control (p<0.025). 
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no significant difference in apoptosis between untreated PHF8 overexpressing cells 
compared to untreated control cells. 
3.5 PHF8 expression down regulates apoptotic genes 
To further investigate the anti-apoptotic effect of PHF8, qRT-PCR was used to observe 
the effect of PHF8 activity on the expression of apoptotic genes that are involved in p53-
mediated apoptosis. HeLa cells with PHF8 knocked down using siRNA or transfected 
with a scrambled control siRNA, were treated with 1.0 µM doxorubicin for 18 hours or 
left untreated prior to RNA extraction. The observed mRNA expression levels were 
normalized to the mRNA levels of the ribosomal protein Rpl13. As shown in figure 3.7 
A, PHF8 mRNA levels were significantly reduced in knockdown cells confirming that 
PHF8 was successfully knocked down in these cells. The mRNA expression levels of p53 
(TP53), Caspase3 (CASP3) and BAX (BAX) were all significantly up-regulated in 
doxorubicin treated PHF8 knockdown cells (Figure 3.7 B, C and D). Total p53 mRNA 
levels were significantly up-regulated in both doxorubicin treated and untreated cells 
when PHF8 was knocked down (Figure 3.7 B). Interestingly, no significant effect was 
seen on the mRNA levels of PUMA in either treated or untreated cells (Figure 3.7 E).  
The same qRT-PCR experiments were repeated in cells overexpressing PHF8. HeLa cells 
were transfected with pFLAG-PHF8-CMV or pFLAG-CMV empty vector. The 
transfected cells were treated with 1.0 µM doxorubicin or left untreated prior to mRNA 
extraction. HeLa cells transfected with FLAG-PHF8 showed significantly higher levels 
of PHF8 mRNA when induced by doxorubicin compared to cells transfected with 
pFLAG-CMV (Figure 3.8 A). In cells overexpressing PHF8, the mRNA expression levels 
of p53, Caspase3 and BAX decreased significantly compared to cells transfected with the 
empty control vector, when cells were treated with doxorubicin (Figure 3.8 B, C and D). 
 
41 
 
 
Figure 3.7: Transcript expression of apoptosis genes when PHF8 is knocked down. 
HeLa cells were transfected with siRNA against PHF8 (siPHF8) or scrambled siRNA 
(siCtrl). Total mRNA was extracted using TRIzol from the siRNA transfected cells 
treated with 1.0μM doxorubicin for 18 hours or from untreated cells.  The mRNA was 
reverse transcribed into cDNA. Primers targeting the apoptotic genes PHF8 (A), TP53 
(B), CASP3 (C), BAX (D) and PUMA (E) were used to analyze levels of mRNA with 
qRT-PCR. Observed mRNA values were normalized to Rpl13. Data presented is the 
mean ±SEM of five biological repeats. *- indicates significant difference from the 
corresponding control (p<0.025). **- indicates significant difference from the 
corresponding control (p<0.1). 
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Figure 3.8: Transcript expression of apoptosis genes with PHF8 overexpressed. Total 
mRNA was extracted using TRIzol, from HeLa cells treated with 1.0μM doxorubicin for 
18 hours or from untreated cells.  The mRNA was reverse transcribed into cDNA and 
primers targeting the apoptotic genes PHF8 (A), TP53 (B), CASP3 (C) and BAX (D) were 
used to analyze levels of mRNA with qPCR. The observed mRNA values were 
normalized to Rpl13 mRNA. Data presented is the mean ±SEM of five biological repeats. 
*- indicates significant difference from the corresponding control (p<0.05). **- indicates 
significant difference from the corresponding control (p<0.1). 
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3.6 PHF8 overexpression reduces p53 protein level 
Since p53 is such an important protein, we found it interesting that PHF8 expression 
appeared to regulate the mRNA expression level of p53. To further confirm the down 
regulation of p53 expression by PHF8, SDS-PAGE and western blot analysis were used 
to observe the effect of PHF8 on p53 protein expression. pFLAG-PHF8-CMV or 
pFLAG-CMV plasmids were transfected into HeLa cells and the effects of PHF8 
overexpression on p53 were observed. The protein expression level of p53 was decreased 
in cells overexpressing PHF8 with or without doxorubicin treatment compared to cells 
transfected with empty vector pFLAG-CMV (Figure 3.9 C). The levels of PHF8 and 
FLAG were also observed using anti-PHF8 and anti-FLAG antibodies respectively 
(Figure 3.9 A, B). To ensure equal loading, the levels of the housekeeping protein β-
tubulin was also observed (Figure 3.9 D). 
3.7 PHF8 binds to the promoters of the p53 and Caspase3 genes 
Since we saw an effect of PHF8 overexpression and knockdown on the mRNA 
expression levels of p53, Caspase3 and BAX, we wondered in PHF8 was directly 
regulating their transcription. To investigate this chromatin immunoprecipitation (ChIP) 
was done to observe PHF8 binding to the promoters of the TP53, CASP3 and BAX genes. 
HeLa cells were transfected with FLAG-PHF8 or pFLAG-CMV and treated with or 
without doxorubicin. Antibodies against either FLAG or RNA polymerase II (PolII) were 
used to immunoprecipitate PHF8 and PolII with their bound DNA. PolII was used as a 
positive control since it should be found at all active promoters. PolII was found to bind 
the promoter of GAPDH (Figure 3.10 E), whereas PHF8 only bound slightly and not 
significantly to the GAPDH promoter compared to the empty vector and IgG controls 
(Figure 3.10 A). Both PHF8 and PolII bound the TP53 promoter significantly compared 
to the pFLAG-CMV and IgG controls (Figure 3.10 B and E), however there was no 
significant difference between doxorubicin treated and untreated cells (Figure 3.10 B). 
PHF8 bound the TP53 promoter significantly more than that of GAPDH (Figure 3.10 A 
and B). PHF8 did not bind to the BAX promoter to the same extent as TP53 or CASP3 
(3.10 D).  
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Figure 3.9: PHF8 overexpression reduces p53 protein levels. pFLAG-PHF8-CMV or 
pFLAG-CMV was transiently transfected into HeLa cells. Cells were either untreated or 
treated with 1.0μM doxorubicin for 18 hours. The cells were lysed and whole cell lysates 
were run on 8% Bis-Tris SDS-PAGE and analyzed by western blot. Blots were analyzed 
using anti-FLAG (A), anti-PHF8 (B), anti-p53 (C) and anti-βtubulin (D). 
 
A 
B 
C 
D 
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Figure 3.10: PHF8 binds the promoter of p53 and Caspase3 but not BAX. Cells over 
expressing PHF8 or an empty vector control (CMV) were fixed with formaldehyde to 
crosslink protein to their bound DNA. PHF8, PolII (E) and IgG were immunoprecipitated 
along with their bound DNA fragments. DNA was purified and GAPDH (A), TP53 (B), 
CASP3 (C) and BAX (D) genes were amplified using qRT-PCR. Values were normalized 
to input DNA. Data presented is the mean ±SEM of four biological repeats. *- indicates 
significant difference from the corresponding empty vector (CMV) and/or no doxorubicin 
control (p<0.05). **- indicates significant difference from the corresponding empty 
vector (CMV) control (p<0.1). 
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Since PHF8 appeared to be directly regulating p53 and Caspase3 transcription we then 
wanted to determine whether or not this regulation was through PHF8 demethylation of 
methylated H3K27. HeLa cells were transfected with siRNA to knock down PHF8 or 
scrambled control siRNA. The cells were treated with doxorubicin or left untreated. Anti-
H3K27me3 was used to immunoprecipitated methylated H3K27 from the samples and 
qRT-PCR analysis was used to analyze the methylation status of H3K27 at the promoters 
of TP53, CASP3 and BAX. As shown in Figure 3-11 B, cells with PHF8 knocked down 
and treated with doxorubicin had a significantly higher level of methylated H3K27 on the 
TP53 promoter than the control siRNA cells. The untreated cells with PHF8 knocked 
down also showed significantly more methylated H3K27 than untreated control cells 
(Figure 3.11 B). Doxorubicin treated PHF8 knock down cells had more H3K27 
methylation of the CASP3 gene compared to cells transfected with scrambled siRNA 
(Figure 3.11 C). GAPDH H3K27 methylation levels were not significantly different 
between PHF8 knockdown cells and the control cells, with the exception of the 
significantly lower levels of H3K27 methylation in untreated control siRNA cells (Figure 
3.11 A).  
The same ChIP experiment was repeated with PHF8 overexpressed in HeLa cells 
transiently transfected with pFLAG-PHF8-CMV or transfected with the empty vector 
pFLAG-CMV. The cells were either treated with doxorubicin or left untreated and 
prepared for ChIP the same as above. Again anti-H3K27me3 was used to 
immunoprecipitate methylated H3K27. Cells with PHF8 overexpressed and treated with 
doxorubicin had a significantly lower level of methylated H3K27 on the TP53 promoter 
than untreated PHF8 overexpressing cells (Figure 3.11 B). CASP3 also displayed 
significantly lower levels of methylated H3K27 when cells were overexpressing PHF8 
and treated with doxorubicin compared to the untreated PHF8 cells and vector control 
cells (Figure 3.11 C). Significantly higher levels of GAPDH H3K27 methylation was 
observed in control cells compared to PHF8 overexpressing cells (Figure 3.11 A). H3K27 
methylation of the GAPDH gene was also significantly lower in cells treated with 
doxorubicin than the same cells untreated (Figure 3.11 A).  
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Figure 3.11: H3K27 methylation of GAPDH, p53 and Caspase3 genes. Cells over 
expressing PHF8 and PHF8 knockdown cells were fixed with formaldehyde to crosslink 
protein to their bound DNA. Anti-H3K27me3 was used to immunoprecipitate DNA 
fragments bound to methylated H3K27. DNA was purified and GAPDH (A), TP53 (B) 
and CASP3 (C) promoter DNA was amplified using qRT-PCR. Values were normalized 
to input DNA. Data presented is the mean ±SEM of four biological repeats. *- indicates 
significant difference from the corresponding SiRNA, empty vector (CMV) or no 
doxorubicin control (p<0.05). **- indicates significant difference from the corresponding 
empty vector (CMV) or no doxorubicin control (p<0.1). 
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Chapter 4  
4 Discussion 
The lysine demethylase PHF8 is a relatively recently discovered protein (Laumonnier et 
al., 2005). It was originally believed that methylation was a static modification until the 
identification of the first demethylase LSD1, which led to the realization that it is in fact a 
dynamic process (Shi et al., 2004). PHF8 is a lysine demethylase known to target 
H3K9me/me2, H3K27me2 (Yokoyama et al., 2010) and H4K20me (Liu et al., 2010). 
The majority of studies done on PHF8 have been on characterizing the role of PHF8 in 
X-linked mental retardation as well as its structure. More recently PHF8 has been 
identified as an oncogene (Björkman et al., 2012). The PHF8 protein has been found to 
have involvement in cell migration, proliferation and cycle progression (Asensio-Juan et 
al., 2012; Björkman et al., 2012; Sun et al., 2013; Liu et al., 2010).  These functions of 
PHF8 have proven to play a role in the progression and pathogenicity of both prostate 
cancer and esophageal squamous cell carcinoma (Björkman et al., 2012; Sun et al., 
2013). The anti-apoptotic effect of PHF8 has also been previously identified to add to its 
oncogenic function (Björkman et al., 2012; Sun et al., 2013), however until now no one 
had investigated the mechanism of how PHF8 affects apoptosis in any detail.  
 
4.1 PHF8 is up-regulated during apoptosis but does not 
demethylate Numb 
PHF8, among other demethylases, was identified as a possible Numb demethylase due to 
its ability to demethylate the histone lysine residues H3K27me/me2 (Yokoyama et al., 
2010) and H4K20me (Liu et al., 2010). These two methylated histone residues share 
similar surrounding sequences to those of the methylated lysines of Numb (K158 and 
K163) (Dhami et al., 2013) (Table 3.1). Quantitative RT-PCR and western blot analysis 
revealed elevated PHF8 levels when apoptosis was induced by doxorubicin in both HeLa 
and U2OS cells (Figures 3.2 and 3.3), which was not seen for any other tested 
demethylase (Figure 3.1). Since other pro-apoptotic genes have been found to be elevated 
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during apoptosis (i.e. PUMA) (Dhami et al., 2013), we initially believed this meant that 
PHF8 has a pro-apoptotic function during apoptosis. We suspected that the pro-apoptotic 
function of PHF8 might have been in demethylating Numb so that it is able to bind to and 
stabilize p53. The mRNA levels of SET8, the methyltransferase responsible for 
methylating Numb, decreased when apoptosis was induced by doxorubicin as shown 
previously (Dhami et al., 2013) (Figure 3.2). Since the methyltranferase expression 
decreases with doxorubicin treatment, we suspected that the Numb demethylase 
expression would increase with doxorubicin treatment, leading us to believe that PHF8 
could be a possible Numb demethylase. Unfortunately, our western blot analysis of 
Numb immunoprecipitated from PHF8 overexpressing cells with and without 
doxorubicin treatment suggested that PHF8 was not involved in Numb demethylation 
(Figure 3.4). Even though PHF8 does not demethylate Numb and has not yet been 
identified to act on any non-histone proteins, it is still possible that PHF8 may target non-
histone proteins. 
Histone modifying proteins have been known to carry out many diverse functions. They 
can act on a number of different genes by modifying the histone tail residues at the 
promoters of their target genes (Shi and Whetstine, 2007). They also sometimes act on 
non-histone proteins, such as SET8 methylating both Numb (Dhami et al., 2013) and p53 
(Shi et al., 2007). The expression level of a given histone modifying enzyme does not 
necessarily change during a certain cellular process that it is or is not involved in. 
Therefore it is possible that a lysine demethylase whose mRNA expression level does not 
change significantly during apoptosis, such as KDM6A (Figure 3.1), may be responsible 
for Numb demethylation or possibly play some other role in apoptosis. Further 
investigation into which demethylase is responsible for demethylating Numb is still 
required. Identification of the Numb demethylase could potentially lead to the 
identification of the demethylase responsible for demethylating p53 K382, which shares 
sequence similarity and the same methyltransferase as Numb K158 and K163 (Dhami et 
al., 2013).  
When observing PHF8 protein levels with doxorubicin treatment, we did not see an 
increase in PHF8 levels at the 6 hour time point (Figure 3.3). In U2OS cells there 
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appeared to be a decrease in PHF8 expression (Figure 3.3). Doxorubicin induces 
apoptosis through intercalation of the chemical into the DNA, causing excessive DNA 
damage (Yang et al., 2014). At the 6 hour time point it is possible that the cells are going 
through the DNA damage response and have not yet entered apoptosis. Therefore since 
we do not see an increase in PHF8 until the 18 hour time point (Figure 3.3), it is unlikely 
that PHF8 plays a role in the DNA damage response. 
 
4.2 PHF8 promotes cell survival 
Further study into PHF8’s effect on apoptosis suggested an anti-apoptotic effect, contrary 
to our originally hypothesis that PHF8 was a pro-apoptotic protein. Flow cytometry 
analysis of PHF8 knockdown (Figure 3.5) and PHF8 overexpressing cells (Figure 3.6) 
demonstrated an anti-apoptotic effect on cells. PHF8 knockdown has previously been 
found to cause an increase in apoptosis (Björkman et al., 2012; Sun et al., 2013), 
however there was no further investigation into the mechanism behind this anti-apoptotic 
effect.  
We decided to explore how PHF8 is negatively affecting p53-mediated apoptotic 
signaling in cells treated with doxorubicin. We found that PHF8 acts, at least in part, by 
down regulating genes required for apoptosis. Our qPCR analysis showed that PHF8 
down-regulates p53, Caspase3 and BAX (Figures 3.7 and 3.8). BAX is a target gene of 
p53 (Miyashita et al., 1994), so it is likely that the effect seen on BAX expression is due 
to the down regulation of p53 by PHF8. PUMA is also an identified p53 target gene for 
p53-mediated apoptosis (Nakano and Vousden, 2001). We expected PHF8 to have a 
negative effect on PUMA mRNA expression since p53 is down regulated by PHF8; 
however we found that PUMA mRNA expression was not significantly affected by PHF8 
(Figure 3.7). It has been suggested that PUMA up-regulation can occur in the absence of 
p53 (Luo et al., 2005; Dhami et al., 2013), therefore it is possible that we do not see an 
effect of PHF8 because PUMA is being regulated by a p53 independent mechanism. It 
would be interesting to observe the effects of PHF8 on other pro-apoptotic genes 
including other p53 target genes, such as Noxa another apoptotic protein. It would also be 
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of interest to observe the possible effects of PHF8 on anti-apoptotic genes. Since PHF8 is 
thought to promote transcription (Feng et al., 2010; Liu et al., 2010), it is possible PHF8 
could be promoting transcription of anti-apoptotic genes to suppress apoptosis.  
The negative effect of PHF8 on p53 expression was also observed at the protein level 
(Figure 3.9). As observed with qPCR, western blot analysis revealed that both the 
untreated and doxorubicin treated cell lysates experienced a decrease in p53 protein 
expression (Figure 3.9). The protein levels of the other apoptotic proteins were not 
analyzed due to limitations of reagent availability. The protein levels should be analyzed 
in the future to confirm the effect seen by qPCR. We would expect to see a decrease in 
protein expression of BAX and Caspase3 as well, at least when the cells are treated with 
doxorubicin. Since the expression levels of p53 was decreased at both the mRNA (Figure 
3.8) and protein level (Figure 3.9) when PHF8 is overexpressed, we can conclude that 
PHF8 is affecting p53 at a transcriptional level, rather than post-translationally.  
Histone modifying proteins typically bind to the gene promoters of the genes they are 
regulating. Chromatin immunoprecipitation revealed that PHF8 directly binds to the 
promoter of TP53 and CASP3, but less significantly to that of BAX with PHF8 binding 
less than 1% of the total DNA (Figure 3.10). This further confirms that PHF8 is directly 
regulating the transcription of TP53 and CASP3. As mentioned above, the negative effect 
seen on BAX mRNA level is likely a result of the inhibition of p53 transcription by PHF8 
(Figures 3.7 and 3.8). However PHF8 has been shown to bind to PolII (Fortschegger et 
al., 2010), therefore it is possible that the localization seen at the promoters of TP53, 
CASP3 and GAPDH could be due solely to this binding.  
Since PHF8 demethylates H3K27me2 (Yokoyama et al., 2010), we decided to investigate 
if PHF8 is regulating the transcription of the affected apoptosis genes through 
demethylation of H3K27me2. A significant increase in H3K27 methylation was seen at 
both the TP53 and CASP3 promoters, when PHF8 was knocked down (Figure 3.11). 
Interestingly, when PHF8 is overexpressed H3K27 methylation at the TP53 and CASP3 
promoters is significantly increased when untreated and significantly decreased when 
treated with doxorubicin, compare to empty vector control cells (Figure 3.11 B and C). 
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These findings suggest that PHF8 is regulating the promoters of TP53 and CASP3 
through demethylation of methylated H3K27. Therefore, although PHF8 may be binding 
to PolII helping localize it to the genes of interest, PHF8 is also directly regulating these 
genes.  
Methylated H3K27 has been described as a transcriptionally repressive mark (Vakoc et 
al., 2006). Therefore the results shown in this study appear to conflict with previously 
published literature. In the qPCR analysis, PHF8 appeared to have a suppressive effect on 
p53 and Caspase3 expression (Figures 3.7 and 3.8). However, the ChIP experiments 
reveal that PHF8 is demethylating H3K27me2, therefore removing a transcriptionally 
repressive mark (Figure 3.11). The ChIP data would suggest a transcriptionally activating 
activity of PHF8 whereas the qPCR data suggest a repressive function. There is likely 
more going on at these promoters that has yet to be identified, including a wide number 
of other histone tail modifications. PHF8 is also responsible for demethylating 
H3K9me/me2 (Yokoyama et al., 2010) and H4K20me (Liu et al., 2010). Therefore these 
ChIP experiments need to be repeated to observe the effect of PHF8 on these histone 
modifications at the TP53 and CASP3 promoters as well. The results may help us to 
better understand the mechanism of PHF8 transcriptional inhibition. It is possible that the 
demethylation of H3K27me2 is required for the recruitment of a repressive transcription 
factor. Another possibility could be that PHF8, although demethylating H3K27me2 may 
also be demethylating a transcriptionally activating transcription factor or histone 
modifying protein, thereby inhibiting the transcriptionally activating function. PHF8 has 
been found to interact with the transcription factors E2F transcription factor 1 (E2F1) and 
host cell factor C1 (HCF-1) as well as the methyltransferase SET1 (Liu et al., 2010), all 
of whose activity PHF8 could be affecting. 
The transcription factor E2F1 has been found to activate p53 transcription in HeLa cells 
(Massip et al., 2013). Since PHF8 has been found to bind E2F1 (Liu et al., 2010), it is 
possible that E2F1 and PHF8 are interacting at the p53 promoter. These two previously 
published findings support our results that identify PHF8 binding to the promoter of p53 
and regulation of p53 transcription. E2F1 is also known to up-regulate pro-apoptotic 
genes in response to genotoxic stress inducing apoptosis (Wu et al., 2009). Methylation 
53 
 
of lysing 158 of E2F1 by SET9 can increase apoptosis, whereas demethylation of this site 
by LSD1 decreases apoptosis (Xie et al., 2011).  PHF8 may be involved in a similar 
mechanism to down regulate p53 and Caspase3 expression.  
 
4.3 PHF8 regulation of p53 
The p53 protein is known to be largely regulated at the post-translational level, since p53 
is continuously being synthesized (Kubbutat et al., 1997). A lot less is known about p53’s 
transcriptional regulation. Recently a number of proteins have been found to activate p53 
transcription during DNA damage response and apoptosis. For example HoxA5 and Pitx1 
have both been found to up-regulate transcription of the p53 gene to promote apoptosis 
(Raman et al., 2000; Liu and Lobie, 2007), whereas the proto-oncogene BCL6 is an 
example of a protein that inhibits p53 transcription (Phan and Ia-Favera, 2004). It is 
possible that PHF8 may be affecting p53 transcription by regulating one of these 
transcription factors through demethylation, either activating BCL6 or inhibiting HoxA5 
or Pitx1.  
We found that PHF8 is regulating the transcription of p53 (Figures 3.7 and 3.8); however 
it may also be directly affecting the p53 protein as well. The p53 protein is known to be 
methylated on a number of lysine residues, many of which the methyltransferases and 
demethylases responsible are unknown (Meek and Anderson, 2009). Lysine residue 382 
of p53 has been found to have sequence similarities to H4K20 (Dhami et al., 2013), a 
target histone tail lysine of PHF8 (Liu et al., 2010). The methyltransferase SET8 is 
known to methylate p53K382 (Shi et al., 2007), however the demethylase responsible for 
its demethylation is unknown. It is possible that PHF8 could be demethylating p53K382. 
Since PHF8 is known to promote cell cycle progression it is possible that PHF8 is 
inhibiting p53 during the cell cycle as well. The effect may be seen more in cancer cells 
which have elevated levels of PHF8, since we did not see much effect of PHF8 without 
doxorubicin treatment. The known role of PHF8 during the cell cycle is promoting the 
G2-M transition (Lim et al., 2013) and the G1-S transition (Liu et al, 2010), whereas p53 
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halts the cell cycle at the G1 to S phase transition when DNA damage is present 
(Kuerbitz et al., 1992). It is possible that PHF8 may be down regulating p53 when p53 is 
not required for cell cycle regulation.  
 
4.4 PHF8 regulation of Caspase3 
The lysine demethylase PHF8 plays a role in neuronal differentiation (Qiu et al., 2010). 
Mutations in the PHF8 gene lead to X-linked mental retardation (XLMR) and cleft lip 
pallet (Laumonnier et al., 2005). Recently Caspase3 has also been found to be involved 
in neurogenesis (Tzeng et al., 2013). Since PHF8 regulates Caspase3 expression during 
p53-mediated apoptosis, it is possible that PHF8 may have an effect on the CASP3 gene 
in neuronal cells during neurogenesis. If PHF8 is somehow regulating Caspase3, this may 
be one way that inactivating mutations of PHF8 leads to XLMR. Further studies are 
needed to investigate this possibility. 
 
4.5 PHF8 as an oncogene 
The down regulation of p53 by PHF8 supports the previously identified oncogenic effects 
of PHF8. The p53 protein plays a very important tumor suppressor role for cells and 
tissues. It blocks cell cycle progression when the cell is experiencing some sort of stress 
or there is DNA damage detected that needs repairing (Kuerbitz et al., 1992; Read and 
Strachan, 1999). Inhibition of the cell cycle by p53 stops the mutation in the DNA from 
being replicated and passed on to daughter cells which could potentially lead to cancer 
(Read and Strachan, 1999). The p53 protein is also involved in the DNA damage 
response and DNA repair itself (Meek, 2009). Finally when the DNA damage is too great 
to be repaired p53 protects the tissue again by signaling for the cell to undergo apoptosis 
(Meek, 2009). We have found that PHF8 inhibits p53 from inducing apoptosis (Figures 
3.6 and 3.8) and although not yet determined, it is possible that PHF8 may be inhibiting 
the transcription of p53 during the cell cycle as well. The suppressive effect that PHF8 
has on p53 could lead to cancer if not properly regulated. 
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It is well known that cancer is the additive result of a number of mutations that lead to the 
hallmarks of cancer (Hanahan and Weinberg, 2000). Therefore it would be unfair to say 
that PHF8 mutations can cause cancer but it could have an oncogenic effect. It is also 
well known that p53 is a highly regulated protein that is acted on by a large number of 
proteins (Meek and Anderson, 2009). Therefore the effect PHF8 has as a single protein 
might not be that significant in vivo. However, since PHF8 is regulating the transcription 
of p53 directly rather than post-translationally (Figures 3.7, 3.8 and 3.10) like the 
majority of other p53 regulating proteins (Meek and Anderson, 2009), PHF8 could have a 
more significant effect on p53. PHF8 also down regulates Caspase3 expression (Figures 
3.7 and 3.8) which is an important protein for apoptosis. Therefore the significant down-
regulation of apoptosis by PHF8 (Figures 3.5 and 3.6) does suggest that it can cause one 
of the hallmarks of cancer; evasion of apoptotic signaling (Hanahan and Weinberg, 
2000).  
There is a lot that remains to be learned about PHF8’s oncogenic functions. So far we 
have only observed the effects PHF8 has on the cell, such as cell cycle progression/ cell 
proliferation, cell migration and apoptosis (Bjorkman et al., 2012; Sun et al., 2013). A lot 
of work is still required to determine the underlying mechanisms causing these oncogenic 
effects. Once we can better understand this protein, we can attempt to develop better 
therapies to target PHF8 in cancer patients with PHF8 overexpression, for custom 
designed treatment programs. 
 
4.6 Therapeutic potential of PHF8 
Cancer treatments typically involve the use of radiation therapy and/or chemotherapy. 
The main goal of these treatments is to kill the cancer cells; unfortunately these 
treatments are not always successful. Sometimes cancer cells have the ability to evade 
apoptosis, which can lead to failed treatments and relapse. Due to its oncogenic anti-
apoptotic effects, PHF8 would make a good target for cancer therapy. Used in 
combination with other treatments, a drug designed to inhibit PHF8 could potentially be 
used to target the cells that are evading apoptosis, making them more susceptible to cell 
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death. There has already been work done to create small peptide inhibitors to block the 
function of lysine methyltransferases and lysine demethylases (Rose et al., 2010). Both 
the PHD domain and the JmjC domain could be targeted on PHF8, however one study 
found that mutating the PHD domain did not inhibit its demethylase activity (Yue et al., 
2010). Therefore, targeting the catalytic JmjC domain would be the best target to inhibit 
PHF8 activity. 
PHF8 and other JmjC containing demethylases require both iron Fe(II) and α-
ketogluterate as co-factors for the catalysis of the demethylation reaction. These 
demethylases can therefore be inhibited by metal chelators such as desferoxamine 
(Barman-Aksözen et al., 2013). α-ketogluterate mimics have also proven to inhibit JmjC 
domain containing demethylases, such as N-oxalyglycine (Hamanda et al., 2009) and 
pyridine-2,4-dicarboxylic acid (Mackeen et al., 2010; Loenarz et al., 2010). 
Unfortunately, chemicals which target co-factor binding to these demethylases are not 
going to be specific to inhibit a specific JmjC demethylase. Small molecule inhibitors 
have also been designed to inhibit JmjC demethylases. Luo et al., (2011) has identified a 
small molecule which mimics a methylated lysine residue connected to an α-ketogluterate 
mimic that is able to bind to and inhibit the JmjC containing demethylase KDM6A. 
Another small molecule, 2-4(4-methylphenyl)-1,2-benzisothiazol-3(2H)-one, another 
metal ion chealator, has been identified to inhibit the JmjC demethylase Jumonji AT-rich 
interactive domain 1B (JARID1B)(Sayegh et al., 2013). Given the observed oncogenic 
activity of PHF8 a small molecule designed to specifically inhibit PHF8 would prove 
beneficial. 
 
4.7 Future directions 
This study has only started to give us insight into PHF8’s anti-apoptotic effects. There are 
many questions that remain to be answered. First, the still unanswered question of which 
lysine demethylase is demethylating Numb during the induction of apoptosis. Further 
investigation into the other suspected demethylases could lead to an answer to this 
question. Next, the biggest question that arises from the findings of this study is how 
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PHF8 is negatively regulating the transcription of p53 and Caspase3. What proteins are 
binding along with PHF8 at the promoters of these genes? How might PHF8 be affecting 
the activity of these proteins? Or how might these proteins affect PHF8 activity? PHF8 
could also be regulating a number of other proteins involved in apoptosis. Does PHF8 
bind to the promoters of other pro-apoptotic genes negatively regulating their 
transcription? Is PHF8 up-regulating any anti-apoptotic proteins during apoptosis? As 
mentioned previously, there is also the possibility that PHF8 could be regulating p53 or 
Caspase3 transcription during other cellular processes, such as whether or not there is any 
effect of PHF8 on p53 during the cell cycle or if PHF8 affects Caspase3 during 
neurogenesis. Future research to answer these questions will give us a better 
understanding of PHF8’s pro-apoptotic activities as well as further insight into the overall 
oncogenic effect of PHF8. 
 
4.8 Conclusions 
In summary, PHF8 has a negative regulatory effect on p53-mediated apoptosis, even 
though its expression levels increase during apoptosis. We found that PHF8 does not 
demethylate Numb as we had initially suspected, which would have been a pro-apoptotic 
effect. Instead, PHF8’s anti-apoptotic effect is at least in part due to its down-regulation 
of the pro-apoptotic genes TP53, BAX and CASP3. PHF8 directly binds to the promoters 
of TP53 and CASP3, demethylating H3K27me2. The negative effect on BAX 
transcription was likely the result of an indirect effect of p53 down-regulation, since 
BAX is transactivated by p53. However, it is unlikely that the inhibition of TP53 and 
CASP3 transcription by PHF8 is simply the result of PHF8 affecting H3K27 methylation. 
H3K27 demethylation is typically thought to have an activating effect on transcription. 
Therefore we suspect other proteins could be involved in the observed transcriptional 
inhibition and that PHF8 possibly could be regulating them. The question of how PHF8 is 
affecting the methylation status of H3K9me/me2 and H4K20me also requires further 
investigation. 
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Appendices  
Appendix A. Raw PHF8 knockdown flow cytometry data of three biological 
replicates. The upper sets of histograms represent the apoptotic cells from samples 
treated with doxorubicin. The lower sets of histograms are the untreated samples. PHF8 
knockdown cells are represented by the red line while control siRNA transfected cells are 
represented in blue. Western blot analysis demonstrates sufficient PHF8 knock down 
(bottom panel). 
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Appendix B: Raw PHF8 over expression flow cytometry data of three biological 
replicates. The upper sets of histograms represent the apoptotic cells from samples 
treated with doxorubicin. The lower sets of histograms are the untreated samples. PHF8 
overexpressing cells are represented by the red line while pFLAG-CMV transfected cells 
are represented in blue. Western blot analysis demonstrates sufficient PHF8 over 
expression (bottom panel). 
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